VCYT — Veracyte, Inc.

Is VCYT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Oversold As of August 19, 2026

Veracyte, Inc. (VCYT) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Diagnostics & Research) last closed at $40.68. The rating moved from Neutral to Oversold on August 14, 2026.

See all oversold Healthcare stocks →

AI analysis

Veracyte, Inc. (VCYT) is positioned to benefit from secular growth in oncology diagnostics and increasing clinical uptake of molecular tests and AI-enabled decision tools. Established commercial products and recurring-test revenue create a defensible revenue base while sector momentum for diagnostics and screening supports upside to volumes. Key near-term catalysts include continued adoption of existing tests, incremental reimbursement wins, and any evidence of margin improvement or cross-sell into new clinical pathways. Principal challenges are reimbursement dynamics, competition from other diagnostics and platform players, and execution risk on expanding test penetration and international growth. Given current market sentiment favoring growth/diagnostic names, the stock has upside potential over the next month, but outcomes will be sensitive to payer actions and commercial execution.

Key factors

  • Strong position in molecular diagnostics with established commercial tests (Afirma, Percepta) that drive recurring, test-volume–linked revenue
  • Positive sector tailwinds: increased diagnostic and screening demand (oncology pathways) which supports higher procedure volumes and downstream genomic/pathology testing
  • Growing adoption of AI and data-driven diagnostics that could expand Veracyte’s addressable market and improve test utility/physician adoption
  • Revenue mix increasingly tied to services and recurring contracts, improving predictability versus one-time procedures
  • Risk-on market tone and constructive sentiment for growth/diagnostic names may support near-term multiple expansion

Risks

  • Reimbursement and payer pressure: insurers/prior authorization changes or negative coverage decisions could materially reduce test volumes or pricing
  • Competitive threats from other molecular diagnostics, large-cap diagnostics players, or novel AI-enabled platforms
  • Execution risk on commercial rollout, sales productivity, and international expansion
  • Regulatory and privacy/legal risk (including FTC or healthcare-specific enforcement) that could raise compliance costs or constrain digital channels
  • Procedure volume sensitivity to macro/geopolitical shocks and episodic declines in physician referrals
  • Concentration risk if a limited set of tests represent a large portion of revenue

See today's live rating, score and targets

Members see the live hourly rating for VCYT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.